FSA Share Fraud Warning

Share fraud includes scams where investors are called out of the blue and offered shares that often turn out to be worthless or non-existent, or an inflated price for shares they own. These calls come from fraudsters operating in 'boiler rooms' that are mostly based abroad.

Please click here to access a copy of the new FSA Share Fraud Warning leaflet, published February 2012

Shareholder Circulars

27 Mar 2012 Notice of Annual General Meeting to be held on 14 June 2012

03 Nov 2011 Notice of General Meeting to be held on 21 November 2011

Investment Strategy

See About Us

The names of the directors and biographical details

See Board

Directors' responsibilities & Committees

See Governance

Country of incorporation and main country of operation

Oxford Pharmascience Group Plc is incorporated in England & Wales (Registration Number 07036758) with England its main country of operation.

Current constitutional documents

Please click on the link below for the Articles of Association

Articles

Details of any other exchanges or trading platforms

The Company is not listed on any other exchanges or trading platforms.

Number of securities in issue

See summary section in Share Price & RNS

Major Shareholders

As at 22 March 2012, shareholders holding more than 3% of the share capital of Oxford Pharmascience Group Plc were:

Holders > 3%	Shares	%
ORA (Guernsey) Ltd	191,904,725	33.26
David Norwood	97,514,300	16.90
Marcelo Bravo	65,000,000	11.26
Robert Quested	37,871,472	6.56
Close Asset Management	30,850,000	5.35
Polar Capital	28,000,000	4.85

Shares not in Public hands

In the terms of the AIM Rules published February 2010 and insofar as it is aware, at 22 March 2012, 65.52% of the Company's AIM securities were not held in public hands.

Shareholder Rights

The rights of shareholders may be different from the rights of shareholders in a UK incorporated company.

Details of any restrictions on the transfer of securities

The following is an abstract from the Admission Document where full details of the placing can be found.

The Directors, David Norwood and ORA have agreed, with the Company and ZAICF (under the terms of the Placing Agreement in the case of the Directors) that they will not (save in certain specific circumstances) dispose of, agree to dispose of or charge any Ordinary Shares or interests in Ordinary Shares for a period of one year following Admission, and then for a further period of one year thereafter to only dispose of Ordinary Shares through the Company's broker from time to time in such manner as the broker may reasonably require in order to maintain an orderly market in the Ordinary Shares of the Company.

Further details of these arrangements are set out in paragraph 13.5 of Part VI of the Admission Document.

Company announcements

See Share Price & RNS

Admission document

Please click on the link below to access the Company's Admission Document dated 08 February 2010.

Admission document

Advisers

Nominated Adviser

ZAI Corporate Finance Ltd
12 Camomile Street
London
EC3A 7PT

Broker

Hybridan LLP
29 Throgmorton Street
London
EC2N 2AT

Reporting Accountants

Baker Tilly Corporate Finance LLP
2 Bloomsbury Street
London
WC1B 3ST

Auditors to the Company

RSM Tenon Audit Limited
The Poynt, 45 Wollaton Street
Nottingham
NG1 5FW

Legal Advisers to the Company

Fasken Martineau LLP
4th Floor
17 Hanover Square
London
W1S 1HU

Legal Advisers to the Nominated Adviser

Faegre & Benson LLP
7 Pilgrim Street
London
EC4V 6LB

Registrars

Capita Registrars
The Registry
34 Beckenham Road
Beckenham
Kent
BR3 4TU